Industry News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 
  • Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP
    13 June 2024

    Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP,

    Glenmark has received final approval by the United States Food and Drug Administration USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC), determined by the FDA to be bioequivalent1 to Nexium.
  • 6 June 2024
    Torrent Pharmaceuticals to market Vonoprazan of Takeda in India
    Torrent Pharmaceuticals has entered into a non-exclusive patent licensing agreement with Takeda to commercialize Vonoprazan in India.
  • 27 May 2024
    Advance DoE Workshop 2024 : A Testament to the Power of Collaboration, education, and innovation

    An exclusive Advance DoE Workshop 2024 hosted by Eminence Business Media, concluded with resounding success, inspiring participants with valuable insights to enhance their experimental design and optimization skills.

  • 15 May 2024
    Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, compared to KEYTRUDA alone, as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV). 

  • 10 May 2024
    FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer
    Patients were randomized (1:1) to receive either tisotumab vedotin 2 mg/kg intravenously every 3 weeks or investigator’s choice of chemotherapy consisting of topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed, until unacceptable toxicity or disease progression.
  • 8 May 2024
    Gland Pharma receives approval for Edaravone Injection

    Gland Pharma Limited, a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL), Single-Dose Bags. 

    The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Radicava Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL) of Mitsubishi Tanabe Pharma Corporation. 

  • 1 May 2024
    EMA recommends marketing authorisation for Truqap
    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Truqap, intended for the treatment of locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations.
  • 1 May 2024
    Lilly Q1 2024 increased by 26 percent driven by Mounjaro, Zepbound, Verzenio and Jardiance

    In Q1 2024, worldwide revenue was USD 8.77 billion, an increase of 26 percent compared with Q1 2023, driven by increases of 16 percent in volume and 10 percent due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio and Jardiance, partially offset by declines in Trulicity.

  • 1 May 2024
    Sanofi has launched GLP-1 drug in India
    Soliqua is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
  • 30 April 2024
    ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

    ONO Pharmaceutical, Co., Ltd and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for USD 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.

Subscribe to Industry News